E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate-to-severely active ulcerative colitis |
Colitis ulcerosa activa moderada o grave |
|
E.1.1.1 | Medical condition in easily understood language |
Moderate-to-severely active ulcerative colitis |
Colitis ulcerosa activa moderada o grave |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045365 |
E.1.2 | Term | Ulcerative colitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1. To evaluate the long-term safety of BI 655130 in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials |
1. Evaluar la seguridad a largo plazo de BI 655130 en pacientes con colitis ulcerosa activa moderada o grave que han finalizado el tratamiento en ensayos anteriores |
|
E.2.2 | Secondary objectives of the trial |
1. To evaluate the long-term efficacy of BI 655130 in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials |
1. Evaluar la eficacia a largo plazo de BI 655130 en pacientes con colitis ulcerosa activa moderada o grave que han finalizado el tratamiento en ensayos anteriores |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female patients, aged ≥18 years 2. Signed and dated written informed consent for 1368.17, in accordance with GCP and local legislation prior to admission into the trial 3. Women of childbearing potential (WOCBP) and men able to father a child must be ready to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information. Note: A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming postmenopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tuba ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. 4. Have completed treatment and the EOT visit in the previous trial and are willing and able to continue treatment in 1368.17. |
1. Varones o mujeres ≥18 años 2. Consentimiento informado por escrito para el ensayo 1368.17 firmado y fechado, de acuerdo a las GCP y a la legislación local antes de la inclusión en el ensayo. 3. Las mujeres fértiles y los hombres que puedan engendrar un hijo deben estar dispuestos a utilizar métodos anticonceptivos de elevada eficacia según ICH M3 (R2) que tengan como resultado una tasa de fallo de menos de 1% al año cuando se usan de forma consistente y correcta. En la información al paciente se incluye una lista de métodos anticonceptivos que cumplen estos criterios. Nota: Una mujer se considera fértil después de la menarquia y hasta ser post-menopáusica, a no ser que sea permanentemente estéril. Los métodos de esterilización permanente incluyen la histerectomía, salpingectomía bilateral y ooforectomía bilateral. La ligadura de trompas NO es un método de esterilización permanente. El estado de post-manopausia se define como 12 meses sin tener la menstruación sin una causa médica alternativa. 4. Haber finalizado el tratamiento y la visita de fin de ensayo en el ensayo anterior y estar dispuesto y capaz para continuar el tratamiento en el 1368.17 |
|
E.4 | Principal exclusion criteria |
1. Have experienced study treatment-limiting adverse events during induction treatment with study drug 2. Have developed any of the exclusion criteria from the original induction study |
1. Haber presentado acontecimientos adversos limitantes para el tratamiento del estudio durante el tratamiento de inducción con el fármaco del estudio 2. Haber presentado alguno de los criterios de exclusión del estudio de inducción original |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. the exposure adjusted rate of patients reporting a treatment emergent adverse event (TEAE) up to week 336 of maintenance treatment |
1. Tasa de pacientes, ajustada por la exposición, que notifiquen un acontecimiento adverso aparecido durante el tratamiento (AAAT) hasta la semana 336 del tratamiento de mantenimiento. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. Up to 336 weeks |
1. Hasta 336 semanas |
|
E.5.2 | Secondary end point(s) |
1. Proportion of patients with clinical remission at week 336 of maintenance treatment |
1. Porcentaje de pacientes con remisión clínica en la semana 336 del tratamiento de mantenimiento. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. Up to 336 weeks |
1. Hasta 336 semanas |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 58 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Belgium |
Canada |
Germany |
Italy |
Japan |
Korea, Republic of |
Netherlands |
Poland |
Russian Federation |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 12 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 12 |